MELBOURNE, Australia, Aug. 4 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited today announced the results of its clinical trial demonstrating that VivaGel® retains antiviral activity against human immunodeficiency virus (HIV) and herpes simplex virus (HSV, the virus that causes genital herpes), following vaginal administration in women.
